Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $2.6 million.

  • Agios Pharmaceuticals' Cash from Financing Activities fell 4719.12% to $2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year decrease of 3992.52%. This contributed to the annual value of $8.7 million for FY2025, which is 3992.52% down from last year.
  • As of Q4 2025, Agios Pharmaceuticals' Cash from Financing Activities stood at $2.6 million, which was down 4719.12% from $4.4 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Cash from Financing Activities registered a high of $7.3 million during Q1 2021, and its lowest value of -$503.5 million during Q2 2021.
  • Its 5-year average for Cash from Financing Activities is -$36.7 million, with a median of $1.2 million in 2022.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash from Financing Activities plummeted by 737914.73% in 2021, and later soared by 375000.0% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$18.6 million in 2021, then skyrocketed by 100.12% to $22000.0 in 2022, then skyrocketed by 3750.0% to $847000.0 in 2023, then skyrocketed by 471.66% to $4.8 million in 2024, then plummeted by 47.19% to $2.6 million in 2025.
  • Its Cash from Financing Activities stands at $2.6 million for Q4 2025, versus $4.4 million for Q3 2025 and $65000.0 for Q2 2025.